Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma

Soukup, Viktor; Kalousová, Marta; Čapoun, Otakar; Sobotka, R.; Breyl, Zuzana; Pešl, Michael; Zima, Tomáš; Hanuš, Tomáš

doi:10.1159/000368166

Cited by 42 publications

(41 citation statements)

References 27 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies have reached the same conclusions but also with critical limitations; however, it is important to note that PGRN has been included in a panel of urinary diagnostic markers for non-invasive detection of primary and recurrent urothelial urinary bladder carcinoma. So far, the analyses that have been performed are inconclusive and it is necessary to carry out larger or multicenter studies to substantiate the benefits of including PGRN in a diagnostic panel [86]. …”

Section: Progranulin As Cancer Biomarkermentioning

confidence: 99%

Progranulin and its biological effects in cancer

et al. 2017

View full text Add to dashboard Cite

Cancer cells have defects in regulatory mechanisms that usually control cell proliferation and homeostasis. Different cancer cells share crucial alterations in cell physiology, which lead to malignant growth. Tumorigenesis or tumor growth requires a series of events that include constant cell proliferation, promotion of metastasis and invasion, stimulation of angiogenesis, evasion of tumor suppressor factors, as well as avoidance of cell death pathways. All these events in tumor progression may be regulated by growth factors produced by normal or malignant cells. The growth factor progranulin has significant biological effects in different types of cancer. This protein is a regulator of tumorigenesis because it stimulates cell proliferation, migration, invasion, angiogenesis, malignant transformation, resistance to anticancer drugs, and immune evasion. This review focuses on the biological effects of progranulin in several cancer models and provides evidence that this growth factor should be considered as a potential biomarker and target in cancer treatment.

show abstract

Section: Progranulin As Cancer Biomarkermentioning

confidence: 99%

Progranulin and its biological effects in cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The aim of the present study was to validate urinary midkine protein, suggested as a convenient biomarker for the non-invasive detection of BCa (17,18), in an independent patient cohort and to compare its diagnostic utility with that of VUC.…”

Section: Discussionmentioning

confidence: 99%

“…Consistently, midkine protein was demonstrated to be highly expressed in various malignancies, including neuroblastoma, breast cancer, hepatocellular carcinoma, colorectal cancer and BCa (15,16). Although the expression of midkine protein in BCa and its correlation with a poor outcome in patients with invasive cancers has been previously reported (16), to the best of our knowledge there are only three studies reporting the measurement of midkine protein in urine specimens from BCa patients (15,17,18). Only one study investigated whether there is a correlation between midkine protein concentration in urine and disease progression in terms of tumor stage and grade (17).…”

Section: Introductionmentioning

confidence: 99%

Validation of the diagnostic utility of urinary midkine for the detection of bladder cancer

et al. 2016

View full text Add to dashboard Cite

As it has been demonstrated previously that midkine (also known as neurite growth-promoting factor 2) protein levels in urine of bladder cancer (BCa) patients are increased compared to healthy controls, the present study validated the diagnostic utility of midkine in an independent patient cohort and compared the observed values with voided urine cytology (VUC), which is the current reference standard for non-invasive diagnosis of BCa. Voided urine samples were prospectively collected from 92 BCa patients and 70 control subjects. Protein levels of midkine were assessed using a commercially available enzyme-linked immunosorbent assay and normalized to urinary creatinine. The diagnostic performance of urinary midkine was evaluated by receiver operating characteristic curves. The best combinations of sensitivities and specificities were determined by Youden's Index. Midkine concentrations were significantly elevated in urine samples from BCa patients compared to controls (P<0.001; Mann-Whitney U Test). The level of midkine was associated with disease progression, with the highest concentrations in urine specimens of patients with pT1 and ≥pT2a, as well as high-grade tumors (P<0.001; Mann-Whitney U test). Sensitivities of urinary midkine and VUC were 69.7 and 87.6%, respectively. The corresponding specificities for midkine and VUC were 77.9 and 87.7%, respectively. The combined use of VUC and midkine improved the sensitivity to 93.3%, but reduced the specificity to 66.2%. Despite its reduced discriminatory power for low-grade and low-stage BCa, urinary midkine can be utilized for the identification of high-grade pT1 and ≥pT2a tumors. This means that midkine may potentially be suitable for the identification of patients with high risk BCa.

show abstract

“…Yoshiki's group (Kageyama, et al 2009) also reported that CALR was highly expressed in urine samples from bladder urothelial carcinoma patients compared to urological patients without urothelial carcinoma and non-urological patients, and suggested that urinary CALR concentration may be a useful biomarker for bladder urothelial carcinoma with a sensitivity of 67.9% and specificity of 80.0%. In another study, urinary CALR was indicated as a potential biomarker for urothelial urinary bladder carcinoma (Soukup, et al 2015). In the human bladder cancer J82 cell line, CALR silencing reduced cell viability, cell cycle progression, adhesion, migration, PXN (Paxillin)/FAK axis activation, FUT1 expression and in vivo tumor growth and metastasis (Lu, et al 2014b;Lu, et al 2011).…”

Section: Bladder Cancermentioning

confidence: 99%

CALR (calreticulin)

Machado-Neto¹,

Campos²,

Trainaen³

2018

Atlas of Genetics and Cytogenetics in Oncology and Haematology

View full text Add to dashboard Cite

Calreticulin (CALR) is a multifunctional protein involved in molecular chaperoning and calcium homeostasis. CALR has also been associated with proliferation, cell cycle progression, migration, invasion and anoikis resistance in cancer cells. The prognostic impact of CALR expression is yet to be elucidated, however in some types of cancer, high CALR expression has been related to worse clinical outcomes. Notably, the discovery of recurrent mutations in the exon 9 of the CALR gene in myeloproliferative neoplasms has opened a new round of investigations. The present review contains data on CALR DNA/RNA, protein encoded and function.

show abstract

Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma

Cited by 42 publications

References 27 publications

Progranulin and its biological effects in cancer

Progranulin and its biological effects in cancer

Validation of the diagnostic utility of urinary midkine for the detection of bladder cancer

CALR (calreticulin)

Contact Info

Product

Resources

About